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Wegener’s granulomatosis is associated with organ-specific
antiendothelial cell antibodies.
Background. Antiendothelial cell antibodies (AECA), usu-
ally detected using human umbilical vein endothelial cells
(HUVEC), are frequently observed in systemic vasculitis, but
their pathogenic role is unclear. Heterogeneity of endothelial
cells necessitates use of clinically relevant endothelial cells for
elucidation of the role of AECA in systemic vasculitis involving
small blood vessels of specific organs.
Methods. Human endothelial cells were isolated from normal
tissue specimens from the nose, kidney, lung, liver, and umbilical
vein. Using flow cytometry, AECA were detected against both
unstimulated and cytokine-stimulated [tumor necrosis factor-a
(TNF-a) and interferon-c (IFN-c)] endothelial cells. Functional
capacity of AECA was determined by complement fixation as-
say. Sera from patients with Wegener’s granulomatosis (16),
limited Wegener’s granulomatosis (8), renal limited disease (4),
microscopic polyangiitis (MPA) (5), rheumatoid arthritis (10),
and systemic lupus erythematosus (SLE) (9), and from healthy
controls (20) were analyzed.
Results. Compared with controls (1) Wegener’s granulomato-
sis is significantly associated with noncytotoxic AECA that se-
lectively bind surface antigens on unstimulated nasal, kidney,
and lung endothelial cells; (2) binding of Wegener’s granulo-
matosis AECA to kidney and nasal endothelial cells in partic-
ular was lost upon treatment with IFN-c and TNF-a; (3) the
two cytokines per se were cytotoxic (30%) to nasal and lung en-
dothelial cells and lysis was further increased (60%) by addition
of systemic vasculitis serum; and (4) Wegener’s granulomato-
sis serum caused agglutination of cytokine-stimulated nasal en-
dothelial cells.
Conclusion. Based on these findings we suggest that AECA
may be one factor involved in the initiation of Wegener’s
granulomatosis. Antigen identification and elucidation of the
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pathogenic roles of AECA and inflammatory cytokines in sys-
temic vasculitis using these cells will be particularly important.
Vasculitis is a term for a group of diseases that in-
volve inflammation in blood vessel walls and forms the
pathologic basis of a diverse group of individual dis-
ease entities. The primary systemic vasculitic diseases,
Wegener’s granulomatosis and microscopic polyangiitis
(MPA), share many common features, including pul-
monary capillaritis, pauci-immune focal necrotizing and/
or crescentic glomerulonephritis, and circulating antineu-
trophil cytoplasmic antibodies (ANCA) [1, 2]. The pres-
ence of ANCA in a large proportion of patients with
systemic vasculitis is well established, although their
pathogenic significance still remains obscure [1–3]. In
Wegener’s granulomatosis patients, ANCA are usually
directed against the enzyme proteinase 3 (PR3-ANCA),
and in MPA patients against myeloperoxidase (MPO-
ANCA) or PR3 [1, 2]. Because both diseases are highly
associated with ANCA, they are sometimes categorized
as ANCA-associated systemic vasculitides (AASV). We-
gener’s granulomatosis is a disease involving granulo-
matous inflammation, necrosis, and vasculitis that most
frequently targets the upper respiratory tract (sinuses,
nose, trachea), lower respiratory tract (lungs), and kid-
neys [1]. MPA is a necrotizing small-vessel vasculitis in-
volving mainly the skin, lungs, and kidneys [2]. However,
an important difference between the two diseases is the
presence of granulomatous inflammation in Wegener’s
granulomatosis, which is not observed in MPA.
Due to the involvement of blood vessel inflammation
in these diseases, interest was already focused on find-
ing antibodies against endothelial cells. Antiendothelial
cell antibodies (AECA) are another population of anti-
bodies with high prevalence in the sera of systemic vas-
culitis patients. AECA have been shown to recognize
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constitutive endothelial cell surface proteins [3–5], and
to fluctuate with the clinical activity of the disease [3,
4]. Evidence exists that AECA from Wegener’s granu-
lomatosis sera can modulate endothelial cell function.
Incubation of human umbilical vein endothelial cells
(HUVEC) with AECA IgG from Wegener’s granu-
lomatosis patients up-regulated the expression of E-
selectin, intercellular adhesion molecule 1 (ICAM-1),
and vascular cell adhesion molecule 1 (VCAM-1/CD106)
[6]. Expression of these surface molecules indicates en-
dothelial activation, and leads to leukocyte adhesion
and diapedesis during an inflammatory response. AECA
bound to HUVEC also induced a parallel increase in
cytokine [interleukin (IL)-1 and IL-6)] and chemokine
[IL-8 and monocytes chemotactic protein-1 (MCP-1)]
production that seems to support the up-regulation
of the mentioned adhesion molecules in an autocrine
fashion [6].
The pathogenic role of AECA is further highlighted
by an experimental model of induced systemic vasculitis
wherein mice immunized with IgG AECA from a patient
with Wegener’s granulomatosis displayed histopatho-
logic signs of both renal and pulmonary vasculitis [7].
Furthermore, patients positive for AECA, but negative
for ANCA, have been found to be at risk of a clinical
relapse [3, 8]. Together, these data support a pathogenic
role for AECA.
Endothelial cells are known to display a heteroge-
neous functional and phenotypic profile, depending on
the anatomic origin and/or vessel type [9]. Therefore, it
is reasonable to suppose that AECA vary in specificities
(i.e., are directed against different target endothelial cell
antigens), depending on the vascular origin. Accordingly,
it has been shown that AECA can target microvascular or
macrovascular endothelial cells [10–13]. So far, the role
of AECA in Wegener’s granulomatosis has been studied
using HUVEC as target cells. Keeping in mind that it is
the small blood vessels of the upper respiratory tract (si-
nuses, nose, ears, and trachea), the lungs, and the kidneys
that are specifically attacked in Wegener’s granulomato-
sis and MPA, we questioned the use of embryonic large
blood vessel endothelial cells such as HUVEC. Thus, we
chose instead to isolate endothelial cells from normal tis-
sue specimens taken from the relevant organs of attack,
namely nose, kidney, and lung for the detection of AECA
in vasculitis sera. Immunoglobulin class and functional
capacity of AECA to lyse these target cells by comple-
ment fixation were also determined.
METHODS
This study has been approved by the local Swedish Eth-
ical Committee.
Monoclonal antibodies, reagents, and cells
Mouse anti-human monoclonal antibodies, unconju-
gated, fluorescein isothiocyanate (FITC)- or phycoery-
thrin (PE)-conjugated, were obtained as follows: CD106
(FITC), CD62E (PE), CD142, and CD144 (BD PharMin-
gen, San Diego, CA, USA); CD105 (FITC), CD141, von
Willebrand factor (FITC), and sheep antihuman IgA
(FITC) (Serotec, Oxford, UK); CD31 (FITC) and Ulex
europaeus (FITC) (Sigma-Aldrich, Munich, Germany);
and acetylated low-density lipoprotein (Ac-LDL)
(FITC) (Molecular Probes, Inc., Eugene, OR, USA).
In addition, goat antihuman IgG and IgM F(ab’)2 frag-
ment (FITC) and goat antimouse IgG (FITC) were
purchased from Jackson ImmunoResearch (Baltimore,
MD, USA); sheep antihuman IgG1, IgG2, IgG3, and
IgG4 (all FITC) (The Binding Site, Birmingham, UK);
goat antihuman IgE (FITC) (BioSource, Camarillo,
CA, USA); mouse antihuman fibroblast and anti-alpha-
actin antibodies (Harlan Sera-Lab, Loughborough, UK)
and mouse antihuman epithelial antigen antibodies
(Dakopatts AB, A¨lvsjo¨, Sweden). Recombinant human
tumor necrosis factor-alpha (TNF-a) and interferon-
gamma (IFN-c) were purchased from R&D Systems
(Abingdon, UK). Rabbit complement was from Cedar-
lane Laboratories Ltd. (Hornby, ON, Canada), and
RPMI 1640 medium was from Gibco (Paisley, UK).
Propidium iodide was from BD Pharmingen. Trypsin-
ethylenediaminetetraacetic acid (EDTA), dispase, per-
coll, collagenase, and 4,6-Diamidino-2-phenylindole
(DAPI) were from Sigma-Aldrich (Stockholm, Sweden).
Human kidney endothelial cells (HKEC), human nasal
endothelial cells (HNEC), and human liver sinusoidal
endothelial cells (HLSEC) were cultivated in endothe-
lial selective medium MCDB 131 (Gibco, Gaithersburg,
MD, USA) containing 10% heat-inactivated human AB
serum, 5 mmol/L L-glutamine, and 100 lg/mL penicillin/
streptomycin (PEST). The medium was further supple-
mented with endothelial cell growth medium (EGM-
2) singlequots (Clonetics, BioWhittaker, Walkersville,
WV, USA) (MCDB complete medium). Primary hu-
man microvascular endothelial cells from lung (HLMEC)
and HUVEC (pooled from >three donors) were pur-
chased from Clonetics and cultivated in recommended
EGM-2-MV medium supplemented with EGM-2-MV
singlequots.
Patients
Thirty-seven sera samples from 24 Wegener’s granulo-
matosis patients, including patients with a limited form
of Wegener’s granulomatosis with only upper airway
involvement and PR3-ANCA (mean age 68 years, 16
men and 12 women) and five patients with microscopic
polyangiitis (MPA) and MPO-ANCA (mean age 81 years,
two men and three women) were studied. Disease entities
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Table 1. Some clinical and demographic data of vasculitis patients at debut (Group 1)
Patient number Diagnosis Gender Age Main organ involvement Treatment Disease activity
1a LWG F 52 ENT No Yes
2a LWG F 74 ENT No Yes
3a WG M 73 ENT, kidney CS Yes
4a WG M 59 ENT, kidney CS Yes
5a WG M 50 ENT, kidney No Yes
6a WG M 76 ENT, lung, kidney No Yes
7a WG M 35 ENT, eye, kidney No Yes
8a RLD M 73 Kidney No Yes
9a WG M 80 ENT, lung, kidney No Yes
10 WG F 53 ENT, kidney No Yes
11 WG M 82 Lung, kidney No Yes
12 WG F 83 ENT, eye, CNS, kidney CS Yes
13 RLD F 89 Kidney No Yes
14 RLD F 76 Kidney No Yes
15 LWG F 40 ENT No Yes
16 LWG M 78 ENT CS Yes
17 LWG M 87 ENT No Yes
18 RLD F 64 Kidney No Yes
19 MPA F 70 Lung, kidney No Yes
20 MPA F 83 Lung, kidney No Yes
21 MPA M 80 GI, kidney No Yes
22 MPA F 86 Joints, kidney No Yes
23 MPA M 87 Heart, kidney No Yes
In remission (group 2)
1a LWG F 52 ENT CS + CP Low
2a LWG F 74 ENT CS + CP Low
3a WG M 73 ENT, kidney CS + CP No
4a,b WG M 59 ENT, kidney CS No
5a WG M 50 ENT, kidney CS + Aza No
6a WG M 76 ENT, lung, kidney CS + CP No
7a WG M 35 ENT, eye, kidney CS + CP No
8a RLD M 73 Kidney CS + CP No
9a WG M 80 ENT, lung, kidney CS + Aza No
24 LWG F 29 ENT CS + Mtx No
25 WG F 77 ENT, kidney No No
26 LWG M 72 ENT, eye CS + CP No
27 WG M 73 ENT, kidney CS + Aza No
28 LWG M 74 ENT, eye CP No
In quiescence (group 3)
29 WG M 67 Eye, kidney No No
30 WG M 82 ENT, eye, kidney CP Low
31 WG M 60 ENT, kidney MTx No
32 WG F 67 ENT, kidney No No
33 WG F 84 ENT, eye, kidney MTx No
Abbreviations are: LWG, limited Wegener’s granulomatosis; WG, Wegener’s granulomatosis; RLD, renal limited disease; MPA, microscopic polyangiitis; ENT, ear,
nose, throat; CS, corticosteroids; CP, cyclophosphamide; MTx, methotrexate; Aza, azathioprine; GI, gastrointestinal tract; CNS, central nervous system.
aPatients were reanalyzed while in remission; bPatient on dialysis.
were defined using the “Chapel Hill Consensus on the
Nomenclature of Systemic Vasculitides” for Wegener’s
granulomatosis and MPA [14]. Renal limited disease
(N = 4) included patients having pauci-immune necro-
tizing glomerulonephritis with or without crescents. Dis-
ease activity was defined according to the Birmingham
vasculitis activity score (BVAS) [15]. The demographic
and clinical characteristics of the vasculitis patients are
presented in Table 1. These patients were divided into
three groups. Group 1 contained 23 patients with newly
diagnosed active disease. Blood samples were collected
before initiation of immunosuppressive therapy. Group
2 contained 14 patients in clinical remission. Nine of the
patients (Table 1) from group 1 were reanalyzed 3 to
11 months later while in remission, while five patients
(24 to 28 in Table 1) were analyzed in clinical re-
mission but not at time of admission. Group 3 con-
tained five patients in quiescence (2 to 10 years after
disease onset). For purpose of simplicity Wegener’s
granulomatosis, limited Wegener’s granulomatosis, and
renal limited disease will be referred to as Wegener’s
granulomatosis.
Ten patients with rheumatoid arthritis (mean age
59 years, four men and six women) and nine patients with
systemic lupus erythematosus (SLE) (mean age 29 years,
one man and eight women) were also included in the
study. All rheumatoid arthritis and SLE patients were
undergoing treatment.
Patient serum samples were separated from blood sam-
ples by centrifugation and stored at –20◦C until use.
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Serum from 20 age- and gender-matched healthy persons
served as controls.
Isolation and cultivation of different target
endothelial cells
Isolation of HNECs. HNECs were isolated from an
approximately 1 cm nose biopsy specimen. After in-
formed consent, patients scheduled for surgery due to
structural nasal deformities, such as septal deviation,
were selected. During the surgical procedure, tissue from
the inferior turbinate was resected using a scalpel with an
atraumatic technique to reduce the damage to the sam-
ple. The tissue was divided into small pieces (approxi-
mately 2 mm) and enzymatically digested using a 0.2%
collagenase solution for 5 to 7 minutes in a 37◦C water
bath. These tissue samples were washed with MCDB 131
medium containing 5% fetal calf serum (FCS) (Gibco)
and placed in 0.2% gelatin-coated wells of a 24-well cul-
ture plate. Each piece was placed in an individual well
and incubated with the endothelial cell–selective medium
MCDB 131 containing 2 ng/mL of vascular endothelial
growth factor (VEGF). After 24 hours, the medium was
further supplemented with 10% heat-inactivated human
AB serum and EGM-2 singlequots. Cells were allowed to
grow out from the nose explants. Areas with endothelial
cell growth were manually picked and grown on sepa-
rate culture plates. HNEC were cultured in MCDB 131
complete medium.
Isolation of human kidney and liver sinusoidal
endothelial cells
Human kidney and liver endothelial cells were iso-
lated from respective healthy organs (intended but not
used for transplantation as no suitable recipient was
found) according to a method described earlier [16, 17].
In short, tissue specimens were manually minced (into
small cubes) and enzymatically digested with dispase
(1.6 U/mL) overnight at 4◦C. Thereafter, the individual
tissue pieces were manually disaggregated with a flat in-
strument to release the endothelial cells. The decanted
cell suspensions were centrifuged at 666g 4◦C for 10 min-
utes and the organ-specific endothelial cells isolated on
a density gradient of 35% percoll (Sigma Chemical Co.,
St. Louis, MO, USA) at 5000g 4◦C for 10 minutes. The
top band of the gradients was collected, the cells washed
in phosphate-buffered saline (PBS), seeded on gelatin-
coated tissue culture flasks and grown at 37◦C in a hu-
midified atmosphere of 5% CO2 in air. In cultures where
fibroblast contamination was observed, the endothelial
cells were hand-picked for further culture. Cell mono-
layers were passaged at confluence using trypsin-EDTA.
HKEC and HLSEC were routinely cultured in MCDB
131 complete medium.
HUVEC and HLMEC were cultured in medium rec-
ommended by the manufacturers.
Phenotyping of endothelial cells
Single-color fluorescence was used to phenotypically
characterize HNEC, HKEC, HLSEC, HUVEC, and
HLMEC. The procedure is described elsewhere [17]. Pri-
mary antibodies for staining were anti-CD141 (throm-
bomodulin), anti-CD142 (tissue factor), anti-CD144
(vascular endothelial-cadherin), anti-AcLDL, anti-Ulex
Europaeus (lectin), anti-CD106 (VCAM-1), anti-CD62E
(E-selectin), anti-CD31 [platelet-endothelial cell adhe-
sion molecule (PECAM)], anti-von Willebrand factor,
anti-CD105 (endoglin), anti-epithelial antigen, anti-
fibroblast, and anti-alpha-actin (smooth muscle cell). The
unconjugated primary antibodies were further stained
with FITC-conjugated goat antimouse secondary anti-
bodies. Intracellular staining for alpha-actin was per-
formed using 5% saponin-treated endothelial cells as
described earlier [18].
Screening of patient sera for antiendothelial cell anti-
bodies using the flow cytometer. In all experiments, one
set of cell samples remained untreated, while another
set was stimulated for 16 hours with recombinant human
IFN-c (200 ng/mL) and TNF-a (20 ng/mL).
For the flow cytometric assay, unstimulated/stimulated
HNEC/HLMEC/HKEC/HLSEC/HUVEC was used for
the screening of AECA in sera of Wegener’s granulo-
matosis, MPA, rheumatoid arthritis, SLE patients, and
healthy controls. Sera from healthy nontransfused blood
group AB males known not to have any antibodies served
as negative controls. A pool of sera from patients who
had formed alloantibodies as a result of multiple blood
transfusions or organ transplantations was used as posi-
tive control. For the assay, 5 × 105 cells were incubated
with 50 lL of patient serum for 1 hour at room temper-
ature, and then washed twice with PBS. Ten microliters
of 1:4 diluted fluoresceinated F(ab’)2 fragments of goat
antihuman IgG (Fc-specific) and antihuman IgM (l chain
specific) antibodies were added and incubated at 4◦C on
ice in the dark for 30 minutes. The cells were washed,
resuspended in 200 lL of PBS and immediately prior
to analysis 4 lL of propidium iodide (50 lg/mL) was
added to detect dead cells. Cells were then analyzed on a
Becton Dickinson flow cytometer (FACSorter) (Becton
Dickinson, Franklin Lakes, NJ, USA). Fluorescence sig-
nals from 10,000 cells were counted and the percentage of
FITC-positive cells was recorded. A shift in the mean flu-
orescence of 20 channels in the test sample as compared to
negative control was considered as positive, determined
as described before [19].
The immunoglobulin class and subclass of AECA in
six Wegener’s granulomatosis sera giving a positive re-
action with HNEC and HKEC were further defined us-
ing sheep antihuman IgG subclass specific IgG1, IgG2,
IgG3, and IgG4 antibodies. Eight Wegener’s granulo-
matosis patients with sufficient serum samples available
were also tested for titers of AECA (1:10, 1:50, 1:100, and
1:200).
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To determine whether the AECA in Wegener’s gran-
ulomatosis sera were directed against blood group his-
tocompatibility antigens, Wegener’s granulomatosis sera
were absorbed against a pool of packed red blood cells,
platelets (express only class I histocompatibility antigens)
and lymphocytes (express both class I and class II histo-
compatibility antigens). For this purpose, 50 lL of pa-
tient serum was added to pooled and packed red blood
cells and incubated overnight at 4◦C. The cells were cen-
trifuged and the serum was separated. The serum was
subsequently absorbed using a similar procedure against
pooled and packed platelets as well as 1 × 106 pooled
lymphocytes. The absorbed sera were once again tested
with HNEC, HKEC, and HLMEC for reactivity as de-
scribed above. Furthermore, reactivity of unabsorbed
Wegener’s granulomatosis sera to a monocytic cell line,
U937 (ATCC, Rockville, MD, USA) and a human renal
epithelial primary cell line (HRE) (Clonetics) was also
performed to test for cross-reactivity with monocytic or
epithelial antigens.
Immunocytochemistry
Tissue culture plates with a 0.2% gelatin coating were
used to grow 3 × 105 HNEC and HKEC. Cells were al-
lowed to attach (24 hours) prior to staining. Cells were left
either untreated or stimulated with IFN-c and TNF-a for
16 hours. For immunocytochemistry, cells were washed
twice with PBS and incubated with either Wegener’s
granulomatosis or MPA or healthy control sera diluted
1:2 (in RPMI 1640 medium) at room temperature for
3 hours. The secondary antibodies used were either FITC-
conjugated goat antihuman IgG or IgM diluted 1:500 (in
PBS). After incubation for 1 hour at 4◦C on ice, the cells
were washed twice with PBS and analyzed under a fluo-
rescence microscope.
Microcytotoxicity assay
The flow cytometric analysis demonstrated that in most
cases the binding of vasculitis AECA was observed with
only unstimulated but not cytokine-stimulated HKEC
and HNEC. Therefore, detection of the functional ca-
pacity of AECA in vasculitis sera using the microcy-
totoxicity assay was performed with only unstimulated
HKEC and HNEC. The method used was as described
earlier [20]. Briefly, the cells were harvested with trypsin-
EDTA, washed once with PBS, and resuspended in cul-
ture medium at a concentration of 3 to 4 × 106 cells/mL.
Prior to addition of 0.5 lL unstimulated HKEC or HNEC,
0.5 lL of vasculitis sera yielding positive reactions in the
flow cytometric analysis were each added to microcyto-
toxicity plates in triplicates. Cells and sera were incubated
for 1 hour at room temperature. Two microliters of rab-
bit complement containing the dyes acridine orange and





Fig. 1. Morphologic characteristics of the isolated endothelial cells.
Morphology of primary (A) human nasal endothelial cells (HNEC),
(B) human kidney endothelial cells (HKEC), (C) human liver sinu-
soidal endothelial cells (HLSEC), (D) human umbilical vein endothe-
lial cells (HUVEC), and (E) human microvascular endothelial cells
from lung (HLMEC) using light microscopy. All cell types showed con-
tact inhibition, and HNEC, HUVEC, and HLMEC showed cobblestone
morphology characteristic of endothelial cells, while HKEC and HLEC
were more spindle-shaped.
bation at room temperature, the reactions were read in
a fluorescence microscope. Reactions were considered
positive when there was lysis of more than 10% above
background as compared to the negative control. Neg-
ative controls consisted of heat-inactivated serum from
normal healthy individuals. In some cases, the vasculitis
sera were inactivated for 1 hour at 56◦C to determine the
role of complement factors in the cytotoxic process.
Statistical analysis
Chi-square test and, when appropriate, Fisher’s exact
test were used to compare categorical parameters. Dif-
ferences were considered significant if P < 0.05.
RESULTS
Culture and morphologic characterization of human
nasal, kidney, and liver endothelial cells
Following isolation, HNEC grew in several clusters that
formed monolayers within 4 to 5 days, and showed contact
inhibition and the cobblestone morphology characteristic
of endothelial cells (Fig. 1A). Within 10 days the HNEC
became confluent. We have previously isolated and used
well-characterized HLSEC at our laboratory [17]. In the
present study, when HKEC or HLSEC were isolated and
plated in gelatin-coated flasks, small adherent clusters of
two to five confluent, cobblestone- and some stellate to
fusiform-shaped cells were noted within 12 to 18 hours.
After about 1 week, these clusters enlarged until they
touched and formed a confluent layer (Fig. 1B and C).
HNEC could be maintained with stable morphology and
growth rate for approximately 10 passages and HKEC
and HLSEC for approximately 18 passages, after which
the cells ceased to divide. HUVEC and HLMEC also
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Table 2. Phenotypic characteristics of endothelial cells isolated from human umbilical vein (HUVEC), kidney (HKEC), nose (HNEC), lung
(HLMEC), and liver (HLSEC)
HUVEC% cells HKEC% cells HNEC% cells HLMEC% cells HLSEC% cells
Antibodies expressing marker expressing marker expressing marker expressing marker expressing marker
CD 141 + (99%) + (98%) + (95%) + (96%) + (100%)
CD 142a + (100%) + (100%) + (100%) + (100%) + (100%)
CD 144 + (100%) + (100%) + (100%) + (100%) + (89%)
Ac-LDL + (100%) + (100%) + (100%) + (100%) + (100%)
Ulex Europaeus + (100%) + (100%) + (100%) + (100%) + (100%)
CD 106a + (100%) + (100%) + (100%) + (100%) + (100%)
CD 62Ea + (73%) − (0%) − (0%) + (68%) − (0%)
CD31 + (100%) − (0%) − (0%) + (100%) − (0%)
von Willebrand factor + (98%) + (95%) + (96%) + (98%) − (0%)
CD105 + (100%) + (100%) + (100%) + (100%) + (100%)
Epithelial antigen − (0.1%) − (0.05%) − (0.05%) − (0.1%) − (0%)
Fibroblasts − (0.005%) − (0.005%) − (0.05%) − (0.01%) − (0.01%)
Alpha-actin − (0%) − (0%) − (0%) − (0%) − (0%)
Ac-LDL is acetylated low-density lipoprotein.
aExpressed only activated endothelial cells.
Table 3. Number and percentage of patients and healthy controls with antibodies against the tested endothelial cells
HUVEC HKEC HNEC HLMEC HLSECPatients
(number) US Sa US Sa US Sa US Sa US Sa
WG (28) 2 (7%) 3 (11%) 20 (71%) 8 (29%) 17 (61%) 3 (11%) 7 (25%) 12 (43%) 0 (0%) 0 (0%)
MPA (5) 0 (0%) 1 (20%) 3 (60%) 0 (0%) 4 (80%) 0 (0%) 3 (60%) 4 (80%) 1 (20%) 2 (40%)
RA (10) 0 (0%) 0 (0%) 1 (10%) 1 (10%) 1 (10%) 1 (10%) 1 (10%) 6 (60%) 0 (0%) 1 (10%)
SLE (9) 9 (100%) 9 (100%) 7 (77%) 7 (77%) 7 (77%) 7 (77%) 5 (55%) 5 (55%) 6 (67%) 6 (67%)
HC (20) 1 (5%) 1 (5%) 1 (5%) 1 (5%) 1 (5%) 1 (5%) 5 (25%) 6 (30%) 0 (0%) 0 (0%)
Abbreviations are: WG, Wegener’s granulomatosis; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; HC, healthy
controls; HUVEC, human umbilical vein endothelial cells; HKEC, human kidney endothelial cells; HNEC, human nasal endothelial cells; HLMEC, human lung
microvascular endothelial cells; HLEC, Human liver sinusoidal endothelial cells; S, stimulated; US, unstimulated.
aCells were stimulated for 16 hours with interferon-gamma (INF-c) (200 ng/mL) and tumor necrosis factor-alpha (TNF-a) (20 ng/mL).
showed the typical cobblestone morphology of endothe-
lial cells (Fig. 1D and E).
Phenotypic heterogeneity of human nasal, kidney, lung,
liver, and umbilical vein endothelial cells
Table 2 shows the differences in the phenotypic char-
acteristics between the various primary endothelial cell
lines. HNEC, HKEC, and HLSEC did not express the
activation marker E-selectin (CD62E) even at 6 and
8 hours after activation, nor did they express the adhesion
molecule PECAM (CD31). However, all endothelial cells
expressed other activation markers VCAM-1 and CD142.
In addition, HLSEC did not express the endothelial cell
associated marker von Willebrand factor confirming our
previous studies [17].
A high frequency of Wegener’s granulomatosis patients
have AECA against human nasal, kidney, and lung
endothelial cells
A significantly higher fraction of Wegener’s granu-
lomatosis patients had AECA that bound to unstimu-
lated HNEC (17/28) (61%) and HKEC (20/28) (71%),
and cytokine-stimulated HLMEC (12/28) (43%) as com-
pared to HUVEC (3/28) (10%) or HLSEC (0/28) (P <
0.0001, P < 0.0001, and P = 0.008, respectively) (Table 3).
In addition, MPA patients showed a similar pattern of re-
activity to the same target endothelial cells as Wegener’s
granulomatosis. This organ-specific pattern of reactivity
was not observed with sera from patients with rheumatoid
arthritis or SLE. Surprisingly, a high fraction of rheuma-
toid arthritis patients reacted strongly with only stimu-
lated HLMEC, while SLE sera reacted with all target
endothelial cells (Table 3). Reactivity to HLMEC was
in general high in all patient groups studied, including
controls. The pattern of AECA reactivity to the various
target endothelial cells in Wegener’s granulomatosis and
MPA patients is shown in Table 4. Three fourths (75%)
of renal limited disease patients had AECA only reac-
tive with HKEC. Five eighths (62.5%) of patients with
Wegener’s granulomatosis limited to the upper respira-
tory tract had AECA against HNEC and/or HLMEC,
while three eighths (38%) of the same patients also had
AECA against HKEC. In addition, 13/16 (81%) of We-
gener’s granulomatosis patients with kidney involvement
had AECA reactivity against HKEC. Thus, in most cases
the pattern of AECA reactivity correlated well with the
clinical organ involvement.
We found that Wegener’s granulomatosis sera posi-
tive for AECA with HNEC, HKEC, and HLMEC when
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Table 4. Antineutrophil cytoplasmic antibodies (ANCA) and antiendothelial cell antibodies (AECA) in vasculitis patients at debut (group 1)
ANCA AECAPatient
number PR3/MPO U/mL HNEC HKEC HLMEC HUVEC HLSEC
1a 35/PR3 – – + + –
2a 65/PR3 + + + – –
3a 290/PR3 + (1:100) + (1:200) + – –
4a 120/PR3 – – – – –
5a 10/PR3 + – + – –
6a 45/PR3 + (1:200) + (1:200) + – –
7a 100/PR3 + (1:100) + (1:200) – – –
8a 105/MPO + + – – –
9a 20/MPO + + + – –
10 100/PR3 + + – – –
11 35/MPO + (1:100) + (1:200) – – –
12 80/MPO – + + – –
13 90/MPO – + – – –
14 500/MPO – + – + –
15 24/PR3 + + + – –
16 50/PR3 + – + + –
17 15/MPO + – + – –
18 45/PR3 – + – – –
19 80 + – + – –
20 150 – + + – –
21 300 + + + – –
22 125 + – – – –
23 75 + + + – –
In remission (group 2)
1a 20/PR3 – – + + –
2a 25/PR3 + + + – –
3a 85/PR3 + (1:50) + (1:50) + – –
4a 25/PR3 – – – – –
5a <10/PR3 + – + – –
6a <10/PR3 + (1:50) + (1:100) + – –
7a <10/PR3 + (1:50) + (1:100) – – –
8a <10/MPO – – – – –
9a <10/MPO – + – – –
24 15/PR3 + + – – –
25 25/MPO + (1:50) + (1:50) – – –
26 <10/PR3 – – – – –
27 <10/PR3 – + – – –
28 <10/PR3 – – – – –
In quiescence (group 3)
29 210/PR3 + + + – –
30 80/PR3 + (1:50) + (1:50) – – –
31 <10/PR3 – – – – –
32 <10/MPO + (1:10) + (1:10) + – –
33 95/PR3 – + – – –
Abbreviations are: HNEC, human nasal endothelial cells; HKEC, human kidney endothelial cells; HLMEC, human lung microvascular endothelial cells; HUVEC,
human umbilical vein endothelial cells; HLSEC, human liver sinusoidal endothelial cells; PR3, proteinase 3; MPO, myeloperoxidase.
aSera from these patients were analyzed at debut and during remission.
absorbed against red blood cells, platelets, and lympho-
cytes retained reactivity to the endothelial cell lines even
after absorption (Fig. 2A). In addition, no reactivity to
the monocytic cell line U937 or renal epithelial cell line
was observed (Fig. 2B).
The detection of ANCA and AECA in the vasculitis
patients is shown in Table 4. All (5/5) newly diagnosed
MPA patients had AECA against either HNEC and/or
HKEC and/or HLMEC. Furthermore, 10/19 (53%) of
patients in remission or quiescence had no detectable
ANCA (<10 units/mL) (Table 4). However, 8/10 (80%)
of these patients had AECA. Thus, a high number of
treated vasculitis patients continued to have AECA,
which is similar to the results obtained with the treated
SLE patients in this study (Table 3). In contrast, the fre-
quency of AECA reacting with HKEC and HNEC in
all treated rheumatoid arthritis patients was significantly
lower as compared to vasculitis patients (P = 0.01 and P =
0.006, respectively, Table 3).
Interestingly, the binding of Wegener’s granulomato-
sis and MPA AECA to HNEC and HKEC was signif-
icantly lost upon cytokine stimulation with IFN-c and
TNF-a as compared to unstimulated cells (P = 0.002
and P = 0.0003, respectively) (Table 3). Similar results
were obtained when cells were stimulated with either
of the cytokines (data not shown); however, a greater
decrease in binding was observed when both cytokines
were added in combination. The loss of AECA binding



















































Fig. 2. Reactivity of sera containing en-
dothelial cell reactive antibodies after absorp-
tion with various target cells. Incubation of
unstimulated primary human nasal (HNEC),
kidney (HKEC), and lung microvascular en-
dothelial cells (HLMEC) with sera from
Wegener’s granulomatosis patients after ab-
sortion with pooled packed red blood cells,
lymphocytes, platelets showed a positive reac-
tion (A). This indicated that the antibodies in
the Wegener’s granulomatosis sera were not
directed against blood group or histocompat-
ibility antigens. In addition no cross-reactivity
of Wegener’s granulomatosis sera to a mono-
cytic cell line U937 and a renal epithelial
primary cell line was observed (B). Represen-
tative result from a single Wegener’s granulo-
matosis patient is shown. Antibody binding
before absorption (gray line), and after ab-
sortion (dashed line) is shown. Negative con-
trol is represented in black.
upon cytokine stimulation was not observed with either
rheumatoid arthritis or SLE sera.
Sera from six Wegener’s granulomatosis patients were
chosen to identify the immunoglobulin class and titers of
the AECA binding to unstimulated HNEC and HKEC.
Using HNEC as target cells, we found that Wegener’s
granulomatosis sera contained a mixture of AECA that
belonged to IgM, IgG, and IgA classes. However, us-
ing HKEC, 6/6 Wegener’s granulomatosis patients had
AECA that belonged to IgG4 and 5/6 also had IgM an-
tibodies. The titers of AECA using HNEC and HKEC
in sera of Wegener’s granulomatosis patients with active
disease was in the range of 1:100 to 1:200, respectively,
while patients in remission and quiescence had AECA
titers of 1:50 and 1:10, respectively (Table 4).
AECA in systemic vasculitis sera bind to cell surface
antigens expressed on human nasal and kidney
endothelial cells
Staining of HNEC and HKEC by immunocytochem-
istry for the binding of systemic vasculitis AECA showed
that these antibodies bind to cell surface antigens
expressed on these target cells (Fig. 3). No green flu-
orescence staining was observed when these cells were
stimulated with IFN-c and TNF-a, indicating once again
the loss/modification of the antigen(s) on the cell surface.
Sera from normal controls did not bind to these target
endothelial cells.
Cytokines IFN-c and TNF-a have a cytotoxic effect on
human nasal and lung endothelial cells
The cytokines IFN-c and TNF-a per se killed in general
approximately 30% HNEC and 40% HLMEC as com-
pared to HKMEC (18%), HLSEC (10%), and HUVEC
(12%) [HNEC and HLMEC vs. HKMEC) (P < 0.0001),
HNEC and HLMEC vs. HLSEC (P < 0.0001), HNEC
and HLMEC vs. HUVEC (P < 0.0001)]. The percent-
age of cell death in the various unstimulated endothelial
cell type is shown in Figure 4A. Importantly, addition of
Wegener’s granulomatosis serum to cytokine-stimulated
HNEC and HLMEC further increased the lysis to ap-
proximately 60% as compared with unstimulated cells
(30%) (Fig. 4). Even more important, the increased ly-
sis of stimulated HNEC was specifically observed with
only serum from the Wegener’s granulomatosis or MPA
patients and not from rheumatoid arthritis or SLE pa-
tients, while increased lysis of stimulated HLMEC was
observed with sera from all groups of patients (Fig. 4B).
On the other hand, addition of Wegener’s granulomato-
sis or MPA serum to cytokine-stimulated HKEC, HLEC,
and HUVEC did not increase cell lysis (Fig. 4B). Cell
death was detected by the addition of propidium iodide
using flow cytometric analysis. An increased cytotoxicity
was observed when both cytokines were added in combi-
nation as compared to either of the cytokines (data not
shown).
AECA do not lyse human nasal, kidney, or lung
endothelial cells in a complement-dependent
cytotoxic assay
We found that Wegener’s granulomatosis sera both in
the presence or absence of complement did not display
any significant cytotoxicity toward unstimulated HNEC
or HKEC. In 7/17 and 2/4 Wegener’s granulomatosis and
MPA patients, AECA killed 10% to 15% (see above) of
unstimulated HNEC, respectively, while 7/20 and 2/3 We-
gener’s granulomatosis and MPA patients had cytotoxic
AECA (10% to 15%) against HKEC, respectively, in the
presence of rabbit complement as compared to negative
controls. Live cells were visualized as green fluorescence
and dead cells as red (Fig. 5). As stated above, cytokine






Fig. 3. Endothelial cell reactive antibodies binding to cell surface antigens. Incubation of unstimulated primary human nasal (HNEC) and kidney
(HKEC) endothelial cells with sera from systemic vasculitis patients showed a positive surface fluorescent staining. Representative result from a
single Wegener’s granulomatosis patient is shown [(A) using fluorescence microscopy, (B) same field under light microscopy; 10×]. No positive
staining with negative control serum (AB serum) was observed (C), while positive staining was observed with the positive control serum (pooled
serum from alloimmunized patients) (D) and Wegener’s granulomatosis serum (E). Cells under higher magnification 40× (C to E). The nucleus
is stained blue using DAPI. Representative result from a single Wegener’s granulomatosis patient using HKEC as target cells is shown [(F), using
fluorescence microscopy, (G) same field under light microscopy; 10×]. (H) Cells under higher magnification 40×. The nucleus is stained blue using
DAPI. DAPI, 4,6-Diamidino-2-phenylindole.
stimulation per se killed approximately 30% of HNEC
(Fig. 5E) as compared to untreated HNEC (Fig. 5A). In-
terestingly, addition of either MPA or Wegener’s granulo-
matosis serum resulted in increased lysis (approximately
40% and 60%, respectively) (Fig. 5F and G). Inactiva-
tion of Wegener’s granulomatosis or MPA sera at 56◦C
did not decrease cell lysis of cytokine-stimulated HNEC
(Fig. 5H) or HLMEC. Addition of positive Wegener’s
granulomatosis serum to cytokine-stimulated HNEC re-
sulted in strong agglutination of the cells. However, no ag-
glutination of stimulated HNEC was observed with MPA
serum.
DISCUSSION
Our results demonstrate for the first time that a signifi-
cantly high fraction of Wegener’s granulomatosis patients
had AECA against human nose, kidney, and lung en-
dothelial cells but not HUVEC, confirming our hypothe-
sis that HUVEC may not always be the suitable target
in AECA assays. Thus, the heterogeneity of endothe-
lial cells from various vascular beds demonstrates that
the use of HUVEC to investigate mechanisms of injury
in small-vessel vasculitis may be both inappropriate and
misleading. The high frequency of AECA found in vas-
culitis sera using HUVEC, as reported in previous studies,
was not reproducible in our study. In most, though not all,
studies [21–25], the binding of AECA to HUVEC has
been demonstrated using formalin- or glutaraldehyde-
fixed cells. Fixation of cells increases both nonspecific
binding and artifacts, which may give false positive re-
sults [26–28]. In the present study, we used unfixed vi-
able endothelial cells. Furthermore, a pooled fraction of
HUVEC from different individuals was used to eliminate
individual differences.
It is well known that endothelial cells have special-
ized functions, depending on the tissue in which they are
located. Vascular endothelium is characterized by hetero-
geneity in morphologic/functional aspects, marker pro-
teins of cell activation, and responsiveness to cytokines
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Fig. 4. Endothelial cell lysis by inflammatory cytokines and effect of
serum addition from various patient groups on these cells. Cell lysis
of unstimulated human nasal (HNEC), lung microvascular (HLMEC),
kidney (HKEC), liver sinusoidal (HLSEC), and umbilical vein endothe-
lial cells (HUVEC) and the same cells treated with sera from Wegener’s
granulomatosis (WG), microscopic polyangiitis (MPA), rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE) patients is shown
(A). HNEC (30%) and HLMEC (40%) were found to be significantly
more susceptible to the cytotoxic effects of interferon-gamma (INF-c)
(200 ng/mL) and tumor necrosis factor-alpha (TNF-a) (20 ng/mL) per
se as compared to HKEC (18%), HLSEC (10%), and HUVEC (12%)
(P<0.0001, P<0.0001, P<0.0001, respectively) (B). Addition of serum
from patients with WG, MPA, RA, SLE to cytokine-treated HNEC and
HLMEC resulted in increased cell lysis, indicating that cytokine stim-
ulation may result in modulation of these cells, making them further
susceptible to reactive components present in serum. The same was not
observed with HKEC, HLSEC and HUVEC. Cell death was detected
by the addition of propidium iodide using the flow cytometric analysis.
Note the increased cell lysis of stimulated-HNEC observed with only
systemic vasculitis sera, indicating a disease-specific phenomenon. The
same was not observed with HLMEC.
[29, 30]. All the endothelial cells isolated in the present
study expressed most of the endothelial-specific cell sur-
face markers; however, some differences were observed,
for example, the lack of the adhesion molecule E-selectin
and PECAM expression on nose, kidney, and liver en-
dothelial cells but not on lung and umbilical vein endothe-
lial cells. Sinusoidal endothelial cells of the liver are well
established as cells lacking the expression of PECAM and
E-selectin [17]. Thus, our results showed both morpho-
logical and phenotypic differences between the EC from
various organs reflecting the vast heterogenity observed
in these cells.
In the present study, two interesting observations were
made regarding the role of AECA: (1) the binding of sys-
temic vasculitis AECA to cell surface antigens expressed
on viable, unstimulated HNEC, HKEC, and HLMEC but
not on HUVEC or HLSEC suggests that these antibodies
are organ-specific and (2) AECA were not lytic, either
in patients with clinical activity or quiescence. Reactiv-
ity of Wegener’s granulomatosis AECA toward HNEC,
HKEC, and HLMEC was not affected even after absorp-
tion of Wegener’s granulomatosis sera with packed and
pooled red blood cells, lymphocytes, and platelets indi-
cating that antibodies are not directed to blood group or
histocompatibility antigens. AECA have been reported
to cross-react with monocytes [31–33] and therefore we
tested Wegener’s granulomatosis sera for cross-reactivity
to a monocytic cell line U937 and a renal epithelial cell
line and found no binding of Wegener’s granulomato-
sis AECA with either of the two cell lines. The exact
specificity of the antigen(s) recognized by AECA will be
important. Interestingly, the same profile of AECA per-
sisted despite remission; however, the titers of AECA
were much lower during remission. Since the numbers of
patients studied were small, we are currently performing
a study with a larger number of Wegener’s granulomato-
sis patients to confirm the shift in titers of AECA during
remission.
Our findings suggest that AECA may be one of the sev-
eral factors involved in the initiation of Wegener’s granu-
lomatosis but may not be directly involved in destruction
of the vessel walls. The organ-specific binding of AECA
in Wegener’s granulomatosis to endothelial cells of the
nose, lung, and kidneys may not result in lysis but in-
stead directly trigger local production of inflammatory
cytokines or alternatively might be instrumental in in-
ducing endothelial phenotype changes [6, 17], resulting
in inflammation or facilitation of cellular infiltration. This
still remains to be proven and such studies are ongoing at
our center. In addition, two important observations were
made regarding the possible role of the inflammatory cy-
tokines IFN-c and TNF-a in Wegener’s granulomatosis.
First, treatment of HNEC and HKEC with IFN-c and
TNF-a induced a loss, or alteration, in the structure or
accessibility of the endothelial cell surface molecules re-
sulting in significantly decreased binding of Wegener’s
granulomatosis AECA to these stimulated cells. This
finding may explain the reason why despite the reports
of high levels of circulating AECA, Wegener’s granulo-
matosis are characterized by the in vivo absence of a clear
antibody deposit in the affected vessel wall [34]. Down-
regulation of the antigen(s) recognized by AECA after
cytokine stimulation has also been described in hemolytic
uremic syndrome (HUS) [35]. However, the antigen has
not yet been identified.
Second, IFN-c and TNF-a per se were cytotoxic to
HNEC and HLMEC but not to HUVEC, HKEC, and
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Fig. 5. Detection of functional capacity of antiendothelial cell antibodies (AECA) in a complement-dependent cytotoxic assay. AECA in sera from
Wegener’s granulomatosis patients did not lyse unstimulated human nasal (HNEC) or kidney (HKEC) endothelial cells in a complement-dependent
cytotoxic assay. A representative result from one Wegener’s granulomatosis patient using HNEC as target cells is shown in (D). This patient had
AECA that killed 10% to 15% unstimulated HNEC in the presence of rabbit complement as compared to negative control. Live cells are visualized
as green fluorescence (A and B) and dead cells as red (C, F to H). Interferon-gamma (INF-c) and tumor necrosis factor-alpha (TNF-a) stimulation
per se killed approximately 30% HNEC (E) as compared to untreated HNEC (A). Interestingly, addition of microscopic polyangiitis (MPA) (F)
and Wegener’s granulomatosis (G) serum resulted in increased lysis (approximately 60%). Addition of Wegener’s granulomatosis (G) but not MPA
(F) serum to stimulated HNEC resulted in strong agglutination of the cells. Inactivation of Wegener’s granulomatosis sera at 56◦C did not decrease
cell lysis (H), indicating that complement components may not play a role in cell death.
HLSEC. Both cytokines have been shown to be cytotoxic
to vascular endothelial cells [36, 37]. Our initial studies
show that cell death induced by these cytokines may not
occur via apoptosis, since the cells did not stain with an-
nexin v but only with propidium iodide even at 4 hours
after cytokine stimulation (preliminary results). We are
currently investigating the reason why specifically HNEC
and HLMEC are susceptible to the cytotoxic effects of
IFN-c and TNF-a. These observations are intriguing and
it would be interesting to test using a larger group of pa-
tients, whether these cytokines may be directly involved
in initiating destruction of the blood vessels in the lungs
and nose of Wegener’s granulomatosis patients.
Addition of Wegener’s granulomatosis and MPA sera
to cytokine-stimulated HNEC and HLMEC further in-
creased cell lysis, indicating that cytokine stimulation may
result in modulation of these cells, making them further
susceptible to reactive components of Wegener’s gran-
ulomatosis and MPA sera. Identification of the serum
components in Wegener’s granulomatosis that may en-
hance lysis of cytokine-stimulated HNEC and HLMEC
will be important. Heat-inactivation of Wegener’s granu-
lomatosis serum did not result in decreased cytotoxicity,
demonstrating that complement components probably
do not play a role in the lytic process, since complement
factors are heat labile and are inactivated at 56◦C.
Furthermore, increased cell lysis of stimulated HNEC
was observed specifically with Wegener’s granulomato-
sis and MPA sera, but not with sera from rheumatoid
arthritis and SLE patients, reflecting a disease-specific
phenomenon in systemic vasculitis. Increased lysis of
stimulated HLMEC was observed with sera from all
groups of patients, indicating differences in sensitivity to
the effects of IFN and TNF by various endothelial cells.
Interestingly, addition of Wegener’s granulomatosis but
not MPA serum to cytokine-stimulated HNEC resulted
in strong agglutination of these cells. However, it is not
possible to draw any conclusions due to the small num-
bers of patients studied.
CONCLUSION
We show that (1) that AECA react better with certain
adult endothelial cells than with HUVEC; (2) that the re-
activity appears to show some correlation with the organ
distribution of disease shown clinically; and (3) cytokine
pretreatment alters both the percentage of binding and
the pattern on immunofluorescence. Thus, using unique
clinically relevant target endothelial cells, we report im-
portant findings that could lead to a better understanding
1060 Holme´n et al: Endothelial cell antibodies in vasculitis
of the complex pathological processes involved in
Wegener’s granulomatosis.
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